The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Optimizing evidence-based, patient-centered care in bladder cancer in community-based settings: A Project ECHO initiative.
 
Matthew Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Research Funding - Accuray (Inst); Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Flare Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoC4 (Inst); PCCTC (Inst); Roche (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape; Prime Education; Research to Practice
(OPTIONAL) Uncompensated Relationships - G1 Therapeutics; Loxo/Lilly
 
Janet Storey
No Relationships to Disclose
 
Ilona Dewald
No Relationships to Disclose
 
Muhammad Sarfraz Nawaz
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Lilly; Gilead Sciences; Janssen Oncology; Pharmacosmos; Pharmaessentia; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Pharmacosmos
 
Samuel Dooyema
No Relationships to Disclose
 
Jeffrey Carter
No Relationships to Disclose
 
Cherilyn Heggen
No Relationships to Disclose
 
Kelly McKinnon
No Relationships to Disclose